ObjectivesThe need for alternative therapies for atopic dermatitis (AD) has emerged due to the side effects of conventional therapies. Biodegradable microneedle acupuncture (BMA) is a novel medical device that overcame the shortcomings of traditional intradermal acupuncture (IDA), such as foreign body feeling and allergic dermatitis. This study aimed to evaluate the efficacy and safety of BMA for patients with Mild to Moderate AD compared with the IDA.MethodsAn assessor-blinded, parallel, non-superiority, randomized controlled pilot trial was conducted. Thirty adult participants were recruited from a single hospital and were equally divided into the experimental or control group. They were treated with BMA or IDA on both sides of LI11, ST36, and PC6 for four hours. Over four weeks, both interventions were performed eight times in total. The primary endpoint was the objective scoring AD (O-SCORAD) index. The secondary endpoints were visual analog scale (VAS) for itch and sleep disturbance, dermatology life quality index (DLQI), skin hydration, and transepidermal water loss (TEWL).ResultsEnrolled thirty participants completed the trial. After the trial, all endpoints remarkably improved compared with the baseline in both groups, except for the TEWL. Between the two interventions, there were no remarkable differences in the fourth week, except for the VAS score for itch and DLQI. No serious adverse events occurred during the study period.ConclusionBoth BMA and IDA were effective in improving Mild to Moderate AD, and they were safe. BMA can be an alternative to conventional acupuncture for patients with sensitive skin, including metal allergies.

25 Feb 2025·Zhen ci yan jiu = Acupuncture research

Effect of electroacupuncture on regulation of the basic fibroblast growth factor/glycogen synthase kinase-3β pathway in Parkinson's disease mice.

Article

Author: Li, Yuan-Yuan ; Wang, Yao ; Bao, Xiao-Li ; Wang, Yan-Chun

OBJECTIVESTo observe the effect of electroacupuncture (EA) on basic fibroblast growth factor (BFGF)/glycogen synthase kinase-3β (GSK-3β) pathway in Parkinson's disease (PD) mice, so as to explore the potential mechanisms of EA in treating PD.METHODSFifty C57/BL6 male mice were randomly divided into the control, model, EA, inhibitor and EA+inhibitor (combination) groups, with 10 mice in each group. The PD mouse model was established by intraperitoneal injection of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine. Mice in the EA group received EA stimulation at "Fengfu" (GV16), "Taichong"(LR3) and "Zusanli"(ST36) for 30 min, once daily for 12 days. The inhibitor group received gavage of fibroblast growth factor receptor (FGFR) inhibitor AZD4547 (12.5 mg·kg^-1·d^-1) for 12 consecutive days. The open box experiment was used to observe the autonomous movement ability of mice. The expression level of tyrosine hydroxylase (TH) in substantia nigra was detected by immunohistochemistry. The apoptosis rate of substantia nigra cells was measured by TUNEL method. The relative protein expression levels of BFGF, phosphorylated phosphatidylinositol 3-kinase (p-PI3K), phosphorylated protein kinase B (p-AKT), p-GSK-3β, B-lymphomatoma-2 gene (Bcl-2), and Bcl associated X protein (Bax) in substantia nigra were detected by Western blot.RESULTSAfter modeling, compared with the control group, the total movement distance was shorten and the duration of rest was prolonged in the open box experiment (P<0.01), the average absorbance of TH in the substantia nigra of the midbrain was decreased (P<0.01), and the apoptosis rate of substantia nigra cells in the midbrain was increased (P<0.01), the protein expression levels of BFGF, p-PI3K, p-AKT, p-GSK-3β and Bcl-2 were decreased (P<0.01), while the expression level of Bax protein was increased (P<0.01) in the model group. Compared with the model and the combination groups, the total movement distance was prolonged and the duration of rest was shorten (P<0.01), the average absorbance of TH was increased (P<0.05), and the apoptosis rate was decreased (P<0.01, P<0.05), the expression levels of BFGF, p-PI3K, p-AKT, p-GSK-3β and Bcl-2 were increased (P<0.01, P<0.05), while the expression level of Bax was decreased (P<0.05) in the EA group.CONCLUSIONSEA at GV16, LR3 and ST36 can alleviate motor disorders, reduce cell apoptosis, protect dopaminergic neurons in mice with PD, which may be related to its effect in regulating the BFGF/GSK-3β pathway.

31 Jan 2025·The FASEB Journal

Electroacupuncture effects on trigeminal neuralgia with comorbid anxiety and depression: The role of frequency and acupoint specificity

Article

Author: Shen, Zu‐Qi ; Yu, Jin ; Liang, Ling‐Feng ; Li, Wei ; Chang, Wei‐Qi ; Zhang, Jia‐Rui ; Wang, Yan‐Qing ; Yin, Xuan ; Xu, Shi‐Fen

AbstractThis study aimed to investigate the effects of electroacupuncture (EA) at specific acupoints (DU20 and ST36) and different frequencies (2 and 100 Hz) on brain regions associated with trigeminal neuralgia, anxiety, and depression. Chronic trigeminal neuralgia was induced by the chronic constriction of the infraorbital nerve (CION). Anxiety and depression were assessed through behavioral tests. The effects of high‐frequency (100 Hz) and low‐frequency (2 Hz) EA at DU20 and ST36 were compared using immunofluorescence staining to evaluate their impact on pain, anxiety, depression, and brain activity. CION induced prominent trigeminal neuralgia in mice, accompanied by anxiety‐ and depression‐like behaviors. Two weeks post‐CION surgery increased neural activity was observed in the Prl, Cg1, CeA, BLA, TRN, CA3, CA1, vlPAG, PC5, and LPB brain regions, while reduced activity was noted in the PVN, VTA, and LDTgv regions. EA at 100 Hz applied to DU20 and ST36 rapidly alleviated pain and specifically reduced despair behavior, a depressive‐like phenotype. In contrast, 2 Hz EA at the same acupoints addressed both anxiety‐ and depression‐like behaviors, modulating a broader range of brain regions, including the PrL, BLA, PVN, VTA, vlPAG, and LDTgv, compared to 100 Hz EA. Repeated 2 Hz EA exclusively at DU20 was sufficient for analgesia and improvement of anxiety and depression, demonstrating a more extensive modulation of brain activity, particularly in the VTA and LDTgv, than EA at ST36. The study reveals that CION induces significant trigeminal neuralgia, accompanied by anxiety and depression, characterized by distinct neural activity patterns. EA at 2 Hz exhibits greater effectiveness in alleviating anxiety and depression, exerting broad modulation across various brain regions. Notably, EA at DU20 demonstrates superior modulation of brain activity and enhanced antidepressant and analgesic effects compared to ST36. These findings provide valuable insights into the nuanced therapeutic effects of EA on the interplay between chronic pain and affective disorders, suggesting potential clinical strategies for intervention.

News (Medical) associated with ST-36

30 Mar 2017

·www.bioportfolio.com

Sapience Therapeutics Inc Pharmaceuticals Healthcare Deals and Alliances Profile [Updated: 21022017] Prices from USD $250

Summary Sapience Therapeutics Inc Sapience is a preclinicalstage biotechnology company which focuses on developing novel therapeutics for major unmet medical needs with special emphasis on high mortality cancers. Its lead candidate, ST36, is a peptidebased drug that acts as a dominantnegative form of the human oncogenic activating transcription factor 5 ATF5. It is being developed to promote tumor cell death of glioblastoma multiforme GBM. Future indications for ST36 include neuroblastoma, leukemia, lymphoma and pancreatic cancer, among others. The company works in partnership with Columbia University to develop ST36 for the treatment of GBM and various additional types of cancer. Sapience is headquartered in Scarsdale, New York, the US. Sapience Therapeutics Inc Pharmaceuticals Healthcare Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions MAs, partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, subsector and regions. GlobalData derived the data presented in this report from proprietary inhouse Pharma eTrack deals database, and primary and secondary research. Scope Financial Deals Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. Deals by Year Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. Deals by Type Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. Deals by Region Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America. Deals by Subsector Chart and table showing information on the number of deals and value reported by the company, by subsector. Major Deals Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's major public companies key financial metrics and ratios. Business Description A brief description of the company's operations. Key Employees A list of the key executives of the company. Important Locations and Subsidiaries A list and contact details of key centers of operation and subsidiaries of the company. Key Competitors A list of the key competitors of the company. Key Recent Developments A brief on recent news about the company. Reasons to Buy Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period. Understand the company's business segments' expansion / divestiture strategy The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy. Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios. Equip yourself with detailed information about the company's operations to identify potential customers and suppliers. The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors. Stay uptodate on the major developments affecting the company Recent developments concerning the company presented in the profile help you track important events. Gain key insights into the company for academic or business research Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs. Note*: Some sections may be missing if data is unavailable for the company.

AcquisitionCollaborate

100 Deals associated with ST-36

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Neuroblastoma	Preclinical	United States	Sapience Therapeutics, Inc.	13 Jul 2016
Glioblastoma	Preclinical	United States	Sapience Therapeutics, Inc.	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

ST-36

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation